Research Article

A Novel Model of Cancer-Induced Peripheral Neuropathy and the Role of TRPA1 in Pain Transduction

Figure 8

Cancer-induced neuropathy and its reversal using the selective TRPA1 antagonist HC-030031: the neuropathic pain (as indicated by cold allodynia) and its reversal in cancer animals injected with 50 and 25 mg/kg and vehicle (n = 6 for each group). The HC-030031 dose of 25 mg/kg restored the cold allodynic pain at 15 minutes (), while the 50 mg/kg dose showed a high significance () at 15 and 30 minutes.